ArticleLeukemia2022
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease.
Abstract read
In one paragraph
Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.Annals of hematology · 2025Pooled it
- When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.Cancers · 2026Review
- Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.Blood cancer discovery · 2026Article
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study.Annals of hematology · 2026Article
- Single-cell RNA Sequencing Identifies Prognostic Biomarkers in Extramedullary Multiple Myeloma.Current medicinal chemistry · 2026Article
- Therapeutic options for extramedullary involvement in multiple myeloma.Clinical and experimental medicine · 2025Review
- Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics.BMC medicine · 2025Article
- Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.BMC cancer · 2025Article
- Review
- Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.European journal of haematology · 2025Article
- Plasma Cell Neoplasms with Spreading in the Blood and Tissues: Extramedullary Myeloma Disease, a Rare Aggressive Form of Multiple Myeloma (First of Two Parts).Mediterranean journal of hematology and infectious diseases · 2025Review
- The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.BMC cancer · 2024Article
- Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report.Cancer reports (Hoboken, N.J.) · 2024Article
- Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Journal of hematology & oncology · 2024Article
- Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Leukemia · 2024Article
- CD38 expression by plasma cells in extramedullary multiple myeloma.Haematologica · 2024Article
- Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from TürkiyeTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.Cancer medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Tomas JelinekDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. tomas.jelinek.md@gmail.com.ORCID http://orcid.org/0000-0002-5467-9253
Tereza SevcikovaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
David ZihalaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Tereza PopkovaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.ORCID http://orcid.org/0000-0001-5885-4218
Veronika KapustovaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Lucie BroskevicovaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Lenka CapkovaInstitute of Biostatistics and Analyses, Ltd, Brno, Czech Republic.
Lucie RihovaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Renata BezdekovaDepartment of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
Sabina SevcikovaBabak Myeloma Group, Department of Pathofysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-7194-6771
Vladimir ZidlikDepartment of Pathology, University Hospital Ostrava, Ostrava, Czech Republic.
Martin HavelDepartment of Nuclear Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Hana PlonkovaDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Alexandra JungovaHematology and Oncology Department, Charles University Hospital Pilsen, Czechia, Czech Republic.
Jiri MinarikDepartment of Hematooncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czechia, Czech Republic.
Martin StorkDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czechia, Czech Republic.
Ludek PourDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Czechia, Czech Republic.
Petr PavlicekDepartment of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Ivan Spicka1st Medical Department-Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital Charles University, Prague, Czech Republic.
Vladimir Maisnar4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
Jakub Radocha4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.ORCID http://orcid.org/0000-0002-5384-8238
Michal SimicekDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Roman HajekDepartment of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.ORCID http://orcid.org/0000-0001-6955-6267
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, MonoclonalAntineoplastic AgentsClone CellsFollow-Up StudiesHumansMultiple MyelomaPlasma CellsPrognosisRetrospective StudiesSurvival RateAntibodies, MonoclonalAntineoplastic Agentsdaratumumab
Identifiers
PMID
34247197What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.